AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2020143 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardioplegic solution (Bretschneider) in Group A
Number of subjects: 427
Study 2020143 — intervention group
Group type: COMPARATOR
Intervention: Intermittent aortic cross‐clamping in Group B
Number of subjects: 427
Study 6749425 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 30040013 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression socks (SOCK)
Number of subjects: 20
Study 30040013 — intervention group
Group type: COMPARATOR
Intervention: Control (CONTROL)
Number of subjects: 20
Study 29150147 — intervention group
Group type: EXPERIMENTAL
Intervention: LAUNCH (18-session clinic and home-based behavioral intervention)
Number of subjects: 151
Study 29150147 — intervention group
Group type: COMPARATOR
Intervention: Motivational interviewing (delivered at the same frequency as LAUNCH)
Number of subjects: 151
Study 29150147 — intervention group
Group type: COMPARATOR
Intervention: Standard care (no formal intervention)
Number of subjects: 151
Study 26683683 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinatumomab (9-μg/day continuous i.v. infusion on days 1-7 and 28-μg/day continuous i.v. infusion on days 8-28 for Cycle 1; subsequent cycles 28-μg/day continuous i.v. infusion on days 1-28)
Number of subjects: 21
Study 26683683 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Number of subjects: 21
Study 25054594 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly interdisciplinary program (WIP) consisting of educational activities, physical therapy, stretching, ergonomics, posture guidance, cognitive behavioral strategies.
Number of subjects: 27
Study 25054594 — intervention group
Group type: COMPARATOR
Intervention: Pain Clinic referral (Control group)
Number of subjects: 27
Study 22209391 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus 10mg once daily
Number of subjects: 416
Study 22209391 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus 10mg once daily (1 previous VEGFr-TKI)
Number of subjects: 416
Study 22209391 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus 10mg once daily (2 previous VEGFr-TKI)
Number of subjects: 416
Study 22209391 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1 previous VEGFr-TKI)
Number of subjects: 416
Study 22209391 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2 previous VEGFr-TKI)
Number of subjects: 416
Study 21157173 — intervention group
Group type: EXPERIMENTAL
Intervention: Gauze frozen with normal saline (n=17)
Number of subjects: 53
Study 21157173 — intervention group
Group type: EXPERIMENTAL
Intervention: Gauze frozen with ice (n=18)
Number of subjects: 53
Study 21157173 — intervention group
Group type: COMPARATOR
Intervention: Wet gauze (n=18)
Number of subjects: 53
Study 17977237 — intervention group
Group type: EXPERIMENTAL
Intervention: keepin' it REAL program
Number of subjects: 4622
Study 15507793 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal calcitonin daily for 6 weeks
Number of subjects: 55
Study 15507793 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 15507793 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal calcitonin
Number of subjects: 55
Study 11835701 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild hypothermia (32-34 degrees C) in Group B
Number of subjects: 44
Study 11835701 — intervention group
Group type: COMPARATOR
Intervention: Normothermia (control group) in Group B
Number of subjects: 44
Study 11835701 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild hypothermia (32-34 degrees C) in Group A
Number of subjects: 44
Study 11835701 — intervention group
Group type: COMPARATOR
Intervention: Normothermia (control group) in Group A
Number of subjects: 44
Study 9744663 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS (100 Hz, tolerable intensity)
Number of subjects: 60
Study 9744663 — intervention group
Group type: COMPARATOR
Intervention: Placebo TENS
Number of subjects: 60
Study 7917695 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic medication (pirenzepine)
Number of subjects: 79
Study 7917695 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic medication (famotidine)
Number of subjects: 79
Study 7917695 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic treatment (either pirenzepine or famotidine)
Number of subjects: 79
Study 7917695 — intervention group
Group type: COMPARATOR
Intervention: Control group (first 36 patients without prophylactic medication)
Number of subjects: 79
Study 3126637 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin (NTG) patch 5 mg/24 hours
Number of subjects: 24
Study 3126637 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin (NTG) patch 10 mg/24 hours
Number of subjects: 24
Study 3126637 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 24
Study 30703703 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity interventions
Number of subjects: 75
Study 30703703 — intervention group
Group type: EXPERIMENTAL
Intervention: Global cognition
Number of subjects: 75
Study 28360247 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrice weekly aerobic exercise training (AT) for 6 months
Number of subjects: 70
Study 28360247 — intervention group
Group type: COMPARATOR
Intervention: Usual care (CON)
Number of subjects: 70
Study 28360247 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrice weekly aerobic exercise training (AT)
Number of subjects: 70
Study 25481281 — intervention group
Group type: EXPERIMENTAL
Intervention: Expert-generated schemas
Number of subjects: 57
Study 25481281 — intervention group
Group type: COMPARATOR
Intervention: Traditional teaching frameworks
Number of subjects: 57
Study 25481281 — intervention group
Group type: EXPERIMENTAL
Intervention: Learner-generated schemas
Number of subjects: 57
Study 24308234 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold lateral condensation technique
Number of subjects: 45
Study 24308234 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermafil technique
Number of subjects: 45
Study 24308234 — intervention group
Group type: EXPERIMENTAL
Intervention: ProTaper gutta‐percha
Number of subjects: 45
Study 21942708 — intervention group
Group type: EXPERIMENTAL
Intervention: NOMAC/E2 (2.5 mg/1.5 mg) in a 24/4-day regimen (n=60)
Number of subjects: 121
Study 21942708 — intervention group
Group type: COMPARATOR
Intervention: LNG/EE (150 μg/30 μg) in a 21/7-day regimen (n=61)
Number of subjects: 121
Study 19220089 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous pentoxifylline (500 mg in 500 mL saline for 2 hours followed by 700 mg in 1000 mL saline for 6 hours)
Number of subjects: 32
Study 19220089 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1500 mL saline)
Number of subjects: 32
Study 15176496 — intervention group
Group type: EXPERIMENTAL
Intervention: Orally inhaled fluticasone propionate (FP) 88 or 220 microg via metered-dose inhaler (MDI)
Number of subjects: 0
Study 15176496 — intervention group
Group type: EXPERIMENTAL
Intervention: Orally inhaled fluticasone propionate (FP) 250 microg via Diskus
Number of subjects: 0
Study 15176496 — intervention group
Group type: EXPERIMENTAL
Intervention: Orally inhaled fluticasone propionate (FP) 250 microg/salmeterol 50 microg via Diskus
Number of subjects: 0
Study 15176496 — intervention group
Group type: COMPARATOR
Intervention: Intranasal fluticasone propionate (FP)
Number of subjects: 0
Study 10404811 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal 17beta-estradiol (50 microg) for 6 weeks
Number of subjects: 22
Study 10404811 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol in combination with oral norethisterone (1 mg) for 6 weeks
Number of subjects: 22
Study 10404811 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo patches for 6 weeks
Number of subjects: 22
Study 10404811 — intervention group
Group type: COMPARATOR
Intervention: Matching oral placebo preparation for 6 weeks
Number of subjects: 22
Study 7564870 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (OM) 20 mg mane
Number of subjects: 55
Study 7564870 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine (RAN) 300 mg nocte
Number of subjects: 55
Study 2406538 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose 1,6-diphosphate (FDP) infusion (250 mg.kg-1 body weight)
Number of subjects: 10
Study 2406538 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 10
Study 6111083 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg pindolol combined with 5 mg clopamide
Number of subjects: 10
Study 6111083 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg metoprolol combined with 12.5 mg hydrochlorothiazide
Number of subjects: 10
Study 31986288 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium chloride (KCl) infusion at rates of 9.4 mmol/h, 12 mmol/h, or 15 mmol/h
Number of subjects: 113
Study 31986288 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 113
Study 31228782 — intervention group
Group type: EXPERIMENTAL
Intervention: Respirator Intervention Phase (RIP) with facemask
Number of subjects: 39
Study 31228782 — intervention group
Group type: COMPARATOR
Intervention: No Intervention Phase (NIP)
Number of subjects: 39
Study 28587952 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine (TMZ) 60mg loading dose at admission, followed by 20mg three times a day
Number of subjects: 173
Study 28587952 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine (TMZ)
Number of subjects: 173
Study 28587952 — intervention group
Group type: COMPARATOR
Intervention: Control group (no TMZ)
Number of subjects: 173
Study 27354782 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate 15.6 µg
Number of subjects: 441
Study 27354782 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 441
Study 24142687 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 0
Study 24142687 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21733320 — intervention group
Group type: COMPARATOR
Intervention: 15 μg cholecalciferol per day
Number of subjects: 212
Study 19684238 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (received removed disc fragments)
Number of subjects: 74
Study 19684238 — intervention group
Group type: COMPARATOR
Intervention: Control group (did not receive removed disc fragments)
Number of subjects: 74
Study 17852442 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating therapy with DFP at 75 mg/kg/day for 4 days/week and DFO at 40 mg/kg/day for 5-7 nights/week
Number of subjects: 60
Study 17852442 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating therapy with DFP and DFO
Number of subjects: 60
Study 17852442 — intervention group
Group type: COMPARATOR
Intervention: DFO alone
Number of subjects: 60
Study 15024929 — intervention group
Group type: EXPERIMENTAL
Intervention: Observed single low-dose mefloquine (15 mg/kg) and artesunate (4 mg/kg)
Number of subjects: 736
Study 15024929 — intervention group
Group type: EXPERIMENTAL
Intervention: Observed single high-dose mefloquine (25 mg/kg) and artesunate (4 mg/kg)
Number of subjects: 736
Study 15024929 — intervention group
Group type: EXPERIMENTAL
Intervention: Observed artesunate 4 mg/kg on day 0 plus self-administered mefloquine 15 mg/kg on day 1 and 10 mg/kg on day 2 with artesunate 4 mg/kg/day on day 1 and 2
Number of subjects: 736
Study 15024929 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-day regimen under direct observation
Number of subjects: 736
Study 15024929 — intervention group
Group type: COMPARATOR
Intervention: Single dose treatments
Number of subjects: 736
Study 15024929 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-day regimens
Number of subjects: 736
Study 15024929 — intervention group
Group type: EXPERIMENTAL
Intervention: All 4 regimens
Number of subjects: 736
Study 11585883 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal-valved Bard Groshong catheter
Number of subjects: 100
Study 11585883 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal-valved Catheter Innovations Pressure Activated Safety Valve catheter
Number of subjects: 100
Study 9679884 — intervention group
Group type: EXPERIMENTAL
Intervention: Melanotan‐II
Number of subjects: 10
Study 9679884 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 8005188 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous terbutaline sulphate
Number of subjects: 12
Study 8005188 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous theophylline
Number of subjects: 12
Study 8005188 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous enprofylline
Number of subjects: 12
Study 8005188 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 12
Study 2563096 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 1007
Study 2563096 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 75 mg once daily
Number of subjects: 1007
Study 2563096 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1007
Study 31345135 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial treatment (IAT) with NCCT ASPECTS 7 to 10
Number of subjects: 205
Study 31345135 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial treatment (IAT) with NCCT ASPECTS 0 to 6
Number of subjects: 205
Study 31345135 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial treatment (IAT) with NCCT ASPECTS
Number of subjects: 205
Study 31345135 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial treatment (IAT) with diffusion weighted imaging ASPECTS
Number of subjects: 205
Study 27808530 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct cause statements (e.g., 'makes', 'increases')
Number of subjects: 0
Study 27808530 — intervention group
Group type: EXPERIMENTAL
Intervention: Can cause statements (e.g., 'can make', 'can increase')
Number of subjects: 0
Study 27808530 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate cause statements (e.g., 'might cause', 'linked', 'associated with')
Number of subjects: 0
Study 26081177 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep deprivation
Number of subjects: 26
Study 24060195 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist-aided exposure therapy
Number of subjects: 70
Study 24060195 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control
Number of subjects: 70
Study 21130474 — intervention group
Group type: EXPERIMENTAL
Intervention: N‐MUF
Number of subjects: 50
Study 19379609 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-derived Lund-Mackay scores calculated by expert rhinologists
Number of subjects: 40
Study 19379609 — intervention group
Group type: COMPARATOR
Intervention: Scores derived from accompanying radiology reports by blinded reviewers
Number of subjects: 40
Study 17309946 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 1411
Study 15024663 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-s interval training (IT20; n=6)
Number of subjects: 20
Study 15024663 — intervention group
Group type: EXPERIMENTAL
Intervention: 180-s interval training (IT180; n=7)
Number of subjects: 20
Study 15024663 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON; n=7)
Number of subjects: 20
Study 12195755 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation of pregnancy during breast cancer treatment
Number of subjects: 0
Study 12195755 — intervention group
Group type: EXPERIMENTAL
Intervention: Potentially curative therapies administered during pregnancy
Number of subjects: 0
Study 12195755 — intervention group
Group type: EXPERIMENTAL
Intervention: Guidelines for managing breast cancer during pregnancy
Number of subjects: 0
Study 12195755 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnancy after treatment for breast cancer
Number of subjects: 0
Study 11477817 — intervention group
Group type: COMPARATOR
Intervention: Embolism chemotherapy (ECT)
Number of subjects: 108
Study 11477817 — intervention group
Group type: EXPERIMENTAL
Intervention: Embolism chemotherapy (ECT) + immunotherapy
Number of subjects: 108
Study 11477817 — intervention group
Group type: EXPERIMENTAL
Intervention: Embolism chemotherapy (ECT) + Chinese herbal medicine
Number of subjects: 108
Study 8017869 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose interferon-beta 1b
Number of subjects: 0
Study 8017869 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2688531 — intervention group
Group type: EXPERIMENTAL
Intervention: Iopromide 300
Number of subjects: 24
Study 2688531 — intervention group
Group type: COMPARATOR
Intervention: Ioxaglate 320 mgI/ml
Number of subjects: 24
Study 4604977 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 160 mg/day
Number of subjects: 49
Study 4604977 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 31188734 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH Agonist
Number of subjects: 80
Study 31188734 — intervention group
Group type: COMPARATOR
Intervention: GnRH Antagonist
Number of subjects: 80
Study 28336412 — intervention group
Group type: EXPERIMENTAL
Intervention: Video assisted laryngoscopy using the King Video Laryngoscope (KVL)
Number of subjects: 82
Study 28336412 — intervention group
Group type: COMPARATOR
Intervention: Direct laryngoscopy (DL)
Number of subjects: 82
Study 26654517 — intervention group
Group type: EXPERIMENTAL
Intervention: General + INB anesthesia (Group B)
Number of subjects: 80
Study 26654517 — intervention group
Group type: EXPERIMENTAL
Intervention: General + epidural anesthesia (Group C)
Number of subjects: 80
Study 26654517 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia (Group A)
Number of subjects: 80
Study 23829055 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertaconazole 2% cream
Number of subjects: 128
Study 23829055 — intervention group
Group type: COMPARATOR
Intervention: Clotrimazole 1% cream
Number of subjects: 128
Study 21668425 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrowband ultraviolet B (NB‐UVB) phototherapy, 210 mJ cm(‐2) starting dose, increased by 10% each time, administered three times per week for 6 weeks.
Number of subjects: 0
Study 21668425 — intervention group
Group type: COMPARATOR
Intervention: Control group received time‐matched exposures to long‐wave UVA radiation.
Number of subjects: 0
Study 18837418 — intervention group
Group type: EXPERIMENTAL
Intervention: Jumbo forceps
Number of subjects: 95
Study 18837418 — intervention group
Group type: COMPARATOR
Intervention: Normal flexible forceps
Number of subjects: 95
Study 16715642 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided Reciprocal Peer Questioning (GRPQ) method
Number of subjects: 0
Study 16715642 — intervention group
Group type: COMPARATOR
Intervention: Traditional senior seminar course
Number of subjects: 0
Study 14530981 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental imagination of a rowing race
Number of subjects: 56
Study 11390337 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunoadsorption (IA) therapy and subsequent immunoglobulin (IgG) substitution
Number of subjects: 25
Study 9015001 — intervention group
Group type: EXPERIMENTAL
Intervention: DDD pacing for 3 months
Number of subjects: 21
Study 9015001 — intervention group
Group type: COMPARATOR
Intervention: AAI pacing for 3 months
Number of subjects: 21
Study 8304047 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal calcitonin (200 IU/day, two times)
Number of subjects: 32
Study 8304047 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 3461385 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 600 mg dose of trimethoprim
Number of subjects: 60
Study 3461385 — intervention group
Group type: COMPARATOR
Intervention: Five-day course of trimethoprim
Number of subjects: 60
Study 30149889 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 0
Study 30149889 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 0
Study 27404012 — intervention group
Group type: EXPERIMENTAL
Intervention: Compensation of US $12.50 conditional on circumcision uptake (food vouchers)
Number of subjects: 903
Study 27404012 — intervention group
Group type: EXPERIMENTAL
Intervention: Lottery-based rewards with high-value prizes
Number of subjects: 903
Study 27404012 — intervention group
Group type: COMPARATOR
Intervention: Control group (no compensation or lottery)
Number of subjects: 903
Study 24092547 — intervention group
Group type: EXPERIMENTAL
Intervention: Transsphenoidal surgery (TS)
Number of subjects: 37
Study 24092547 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin analogs (SAs)
Number of subjects: 37
Study 24092547 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegvisomant (PGV)
Number of subjects: 37
Study 24092547 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 37
Study 24092547 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment effect
Number of subjects: 37
Study 22417905 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA cream (5%)
Number of subjects: 134
Study 22417905 — intervention group
Group type: EXPERIMENTAL
Intervention: Lubricant gel
Number of subjects: 134
Study 22417905 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 134
Study 20733209 — intervention group
Group type: EXPERIMENTAL
Intervention: Crowd noise
Number of subjects: 0
Study 20733209 — intervention group
Group type: COMPARATOR
Intervention: No crowd noise
Number of subjects: 0
Study 18226326 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe/simvastatin 10/20 mg combination tablet (EZE/SIMVA)
Number of subjects: 367
Study 18226326 — intervention group
Group type: COMPARATOR
Intervention: Doubling statin dose
Number of subjects: 367
Study 16335010 — intervention group
Group type: EXPERIMENTAL
Intervention: Diaspirin cross‐linked hemoglobin (DCLHb)
Number of subjects: 28
Study 14517196 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib 60 mg once daily for mild hepatic insufficiency patients
Number of subjects: 0
Study 14517196 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib 60 mg every-other-day for moderate hepatic insufficiency patients
Number of subjects: 0
Study 14517196 — intervention group
Group type: EXPERIMENTAL
Intervention: Single intravenous doses of etoricoxib for both mild and moderate hepatic insufficiency patients
Number of subjects: 0
Study 10877373 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine 0.2%
Number of subjects: 219
Study 10877373 — intervention group
Group type: COMPARATOR
Intervention: Timolol 0.5%
Number of subjects: 219
Study 9106321 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroreflexotherapy intervention
Number of subjects: 78